- Zai Lab (ZLAB, Financial) is set to present phase 1 trial data for its DLL3-targeted ADC, ZL-1310, at the 2025 ASCO Annual Meeting.
- The trial focuses on patients with extensive-stage small cell lung cancer (ES-SCLC) who have undergone prior platinum-based chemotherapy.
- An investor conference call to discuss the trial's findings is scheduled for June 2, 2025.
Zai Lab Limited (ZLAB) has announced that it will be presenting updated data from its ongoing global Phase 1a/1b clinical trial of ZL-1310 at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting. This trial evaluates ZL-1310, a Delta-like ligand (DLL3) antibody-drug conjugate (ADC), targeting extensive-stage small cell lung cancer (ES-SCLC), particularly in patients previously treated with platinum-based chemotherapy regimens.
The presentation is scheduled for a poster session at the McCormick Place Convention Center, Chicago, from May 30 to June 3, 2025. ZL-1310 has been recognized with an Orphan Drug Designation by the U.S. FDA due to its potential to address the treatment needs in SCLC and neuroendocrine tumors.
An investor conference call and webcast will be held on June 2, 2025, at 7:00 a.m. CT to discuss the updated data and future clinical development plans for ZL-1310. Investors are encouraged to register for the webcast to gain insights directly from the presentation provided by Rafael G. Amado, M.D., the President and Head of Global Research and Development at Zai Lab.
